Moderna shares tumbled nearly 17 on Monday after the drugmaker slashed its 2025 revenue forecast by $1 billion and announced plans to cut $1.5 billion in expenses this year. The company faces challenges balancing rising drug development costs with declining demand for Covid-19 treatments and slow adoption of its RSV medication. The $30 support level aligns with the April 2019 high and March 2020 Covid-era volatility, presenting a potential buying opportunity. Failure to hold this level could lead to a retest of $13, near the December 2018 and August 2019 lows, attracting bargain hunters.